Galectin Therapeutics Inc (NASDAQ:GALT)’s traded shares stood at 0.44 million during the latest session, with the company’s beta value hitting 0.72. At the last check today, the stock’s price was $2.14, to imply an increase of 1.90% or $0.03 in intraday trading. The GALT share’s 52-week high remains $4.27, putting it -99.53% down since that peak but still an impressive 27.57% since price per share fell to its 52-week low of $1.55. The company has a valuation of $134.62M, with an average of 0.35 million shares in intraday trading volume over the past 10 days and average of 171.49K shares over the past 3 months.
Galectin Therapeutics Inc (NASDAQ:GALT) trade information
After registering a 1.90% upside in the latest session, Galectin Therapeutics Inc (GALT) has traded red over the past five days. The 5-day price performance for the stock is -25.78%, and -23.67% over 30 days. With these gigs, the year-to-date price performance is 29.22%. Short interest in Galectin Therapeutics Inc (NASDAQ:GALT) saw shorts transact 5.52 million shares and set a 42.37 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Galectin Therapeutics Inc (GALT) estimates and forecasts
Looking at statistics comparing Galectin Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Galectin Therapeutics Inc (GALT) shares are -17.50% down over the last 6 months, with its year-to-date growth rate lower than industry average at 1.35% against 16.60%.
GALT Dividends
Galectin Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Galectin Therapeutics Inc (NASDAQ:GALT)’s Major holders
Galectin Therapeutics Inc insiders hold 30.95% of total outstanding shares, with institutional holders owning 15.77% of the shares at 22.85% float percentage. In total, 15.77% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 2.12 million shares (or 3.4143% of shares), all amounting to roughly $4.78 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 1.56 million shares, or about 2.5232% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.53 million.
